Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global ‘Fair Access’ Coronavirus Vaccine Fund Launched, AZ Doubles Output Target

Company Aims For Two Billion Doses A Year

Executive Summary

Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.

You may also be interested in...



Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race

Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.

Coronavirus Update: WHO Aims For 2 Billion Doses, Oral Vaccine Selected For Warp Speed

As vaccine development progresses, worldwide deaths caused by SARS-CoV-2 continue to rise, and now exceed 500,000, with more than 10 million confirmed cases. Daily new infections also hit a new peak, as some US states are being forced to consider lockdowns again as the situation worsens.

Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients

Recruiting the right patient population for Phase III trials of COVID-19 vaccines will be a key factor in how fast any candidate can come to market. The challenge, which will likely mean enrolling patients who often are underrepresented in trials, is keeping Moderna's Chief Medical Officer up at night. The company also talked vaccine distribution, what it feels it owes the US government for its financial support, and pricing of its potential mRNA vaccine on a recent New York Academy of Sciences webinar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel